- Home
- BEAT vs PYXS Comparison
BEAT vs PYXS Comparison
Compare BEAT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- PYXS
- Stock Information
- Founded
- BEAT 2015
- PYXS 2018
- Country
- BEAT United States
- PYXS United States
- Employees
- BEAT N/A
- PYXS N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- PYXS Health Care
- Exchange
- BEAT Nasdaq
- PYXS Nasdaq
- Market Cap
- BEAT 59.0M
- PYXS 66.3M
- IPO Year
- BEAT 2021
- PYXS 2021
- Fundamental
- Price
- BEAT $1.80
- PYXS $1.33
- Analyst Decision
- BEAT Buy
- PYXS Strong Buy
- Analyst Count
- BEAT 1
- PYXS 5
- Target Price
- BEAT $8.00
- PYXS $9.00
- AVG Volume (30 Days)
- BEAT 74.8K
- PYXS 416.4K
- Earning Date
- BEAT 05-13-2025
- PYXS 05-15-2025
- Dividend Yield
- BEAT N/A
- PYXS N/A
- EPS Growth
- BEAT N/A
- PYXS N/A
- EPS
- BEAT N/A
- PYXS N/A
- Revenue
- BEAT N/A
- PYXS N/A
- Revenue This Year
- BEAT N/A
- PYXS N/A
- Revenue Next Year
- BEAT N/A
- PYXS N/A
- P/E Ratio
- BEAT N/A
- PYXS N/A
- Revenue Growth
- BEAT N/A
- PYXS N/A
- 52 Week Low
- BEAT $1.45
- PYXS $0.83
- 52 Week High
- BEAT $3.48
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- BEAT 56.41
- PYXS 56.20
- Support Level
- BEAT $1.50
- PYXS $1.20
- Resistance Level
- BEAT $1.90
- PYXS $1.27
- Average True Range (ATR)
- BEAT 0.13
- PYXS 0.07
- MACD
- BEAT 0.02
- PYXS 0.00
- Stochastic Oscillator
- BEAT 75.00
- PYXS 83.33
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.